Background. Henoch-Schönlein purpura (HSP) is a systemic disorder characterized by leukocytoclastic vasculitis involving the capillaries and by the deposition of IgA immune complexes. An association between HSP and atypical bacteria is uncommon in children. Methods and Results. Here we report three cases of children, aged 5, 4 and 16 years, who were diagnosed with HSP associated with Mycoplasma pneumoniae or Chlamydia pneumoniae infection. In all presented cases, persistent cutaneous manifestations and abdominal pain were resistant to antibiotics and corticosteroids, but resolved during 48 h after the introduction of dapsone. No adverse effects of treatment were observed. Conclusion. Dapsone, a sulphone with an anti-inflammatory activity, showed remarkable therapeutic efficacy against rash and gastrointestinal symptoms in children with HSP. Its administration should be considered particularly in persistent cutaneous form of HSP.
INTRODUCTION
Henoch-Schönlein purpura (HSP) is a small vessel vasculitis resulting from immunoglobulin A (IgA)-mediated inflammation. It is the most common acute systemic vasculitis of childhood mainly affecting skin, gastrointestinal tract, joints and kidneys. Increased polymeric IgA production by mucosal immune system in response to a mucosally presented antigen, such as bacteria, viruses, or fungi, has been considered an underlying mechanism for HSP. In an acute phase of HSP, increased concentrations of pro-inflammatory cytokines which can cause damage to the endothelium such as TNF-α, can be detected 1 . HSP is usually self-limiting with spontaneous resolution of symptoms within 2 months, however, recurrence occurs in approximately one third of cases 2 . Relapses mostly manifest as a new episode of rash that is often associated with gastrointestinal and renal symptoms. Articular and gastrointestinal involvement at the time of diagnosis is predictive of relapse 2 . Some patients suffer from chronic cutaneous form of HSP and recurrent abdominal pain.
Arthralgia and painful soft tissue edema usually respond to acetaminophen or nonsteroidal anti-inflammatory drugs. Oral prednisone (1-2 mg/kg day) may be necessary to accelerate their effect, however, corticosteroid therapy does not prevent the development of progressive renal disease. Immunosuppressants (azathioprine, oral cyclophosphamide and mycophenolate) are used as corticosteroid-sparing agents or as an add-on therapy in patients with severe renal involvement 3 . Sporadic reports suggest that dapsone may accelerate resolution of the palpable rash (Table 1 ) (ref. [4] [5] [6] [7] [8] [9] [10] [11] [12] ).
Here we report three cases of HSP associated with atypical bacterial infections -Mycoplasma pneumoniae and Chlamydia pneumoniae -with relapsing cutaneous manifestations and abdominal pain, which were alleviated by dapsone treatment. Diagnosis of HSP was based on the criteria of the Paediatric Rheumatology European Society (PRES), European League Against Rheumatism (EULAR) and Pediatric Rheumatology International Trials Organisation (PRINTO) (ref. [13] [14] [15] [16] ).
CASE REPORT 1
A previously healthy 5-year-old girl was admitted to a regional hospital due to periumblical pain and severe palpable purpuric rash involving buttocks and legs. Oral penicillin was given for 10 days due to positivity of the pharyngeal swab for Streptococcus pyogenes, however, her general condition worsened and purpuric lesions extended to the arms, abdomen and face. Oral prednisone (2 mg/kg/day) was ineffective in controlling skin lesions and abdominal pain. After transferring to our department, she had leukocytosis (WBC; 21,900/µL), elevated C-reactive protein (CRP; 37 mg/dL) and D-dimers (865 ng/mL). Stool analysis revealed occult blood while urinalysis was negative. Chlamydia-specific IgM antibodies were positive (Chlamydia IgG, IgM, IgA r-ELISA, EIA, MEDAC Germany). Other possible autoimmune condi-tions and infections (such as EBV, CMV, hepatitis A, B, C, Yersinia and Mycoplasma) were excluded. Skin biopsy from the lesion showed infiltration of small vessels in the dermis by leukocytes with nuclear dust and extravasation of erythrocytes confirming leukocytoclastic vasculitis. Clarithromycin at a dose of 15 mg/kg/day was given for 14 days, however, abdominal pain and purpura on the legs reappeared 1 week after its cessation. Dapsone (0.5 mg/kg/day) was introduced 2 months after HSP onset. Due to persisting purpura and abdominal pain after 2 weeks, the dose was increased to 1 mg/kg/day followed by regression of rash and relief from abdominal pain within 48 h. The treatment was finished after 6 weeks without any adverse effect (methemoglobin level was 1.6%). Less intense palpable purpura occurred four times during the next 12 months.
CASE REPORT 2
A 4-year-old boy was admitted to a regional hospital with two-week history of rhinitis, nausea, vomiting and abdominal pain. One day later, he developed palpable purpuric rash involving buttocks and legs and angioedema (non-pitting edema) of eyelids and face. Laboratory tests showed leukocytosis (WBC 34,000/µL) and elevated CRP (31.4 mg/dL). Fecal occult blood test was positive. Amoksiklav was given for 10 days due to incidental tonsilitis and prednisone (2 mg/kg/day) was added due to recurrent abdominal pain for two weeks. The boy was transferred to our department, where we excluded infections with Streptococcus, Helicobacter, Yersinia, Chlamydia, Coxsackie, hepatitis, CMV, EBV, parvovirus and Toxocara, but confirmed positivity of Mycoplasma pneumoniae antibodies (LIAISON Mycoplasma pneumoniae IgM, IgG, DIASORIN Ireland, CLIA). Clarithromycin (15 mg/ kg/day) was continued for 14 days. Subsequently, due to recurrent abdominal pain and purpura, dapsone (1 mg/ kg/day) was given for 4 weeks and symptoms completely resolved within 48 h.
CASE REPORT 3
A 16-year-old boy was treated by dermatologist for a non-pruritic maculopapular rash of legs with topical beclomethasone dipropionate. Within two months, ecchymoses and petechiae appeared on his legs, arms and trunk despite treatment. Clarithromycin was given for 21 days due to elevated titer of Mycoplasma pneumoniae antibodies without improvement of the skin lesions. At our clinic, other causative agents and autoimmune disorders were excluded. Dapsone (1 mg/kg/day) was introduced after 6 months from disease onset followed by marked improvement within a few days (Fig. 1) .
The patients' parents provided informed consent for publication. A B 
DISCUSSION
Association of HSP with atypical bacterial infections may occur but is infrequent in children [17] [18] [19] . Interestingly, patients who suffered relapse of HSP had less frequent history of upper respiratory tract infections (31% vs. 42%) (ref.
2 ). Dapsone (diaminodiphenylsulfone) was first synthesized in 1908 by Fromm and Whittmann. During the 1950s, sulfones were shown to possess an anti-inflammatory activity in dermatitis herpetiformis and subcorneal pustular dermatosis (Sneddon-Wilkinson syndrome) and their anti-inflammatory properties have increasingly been used in the treatment of dermatologic disorders 20 . In vitro studies demonstrated that dapsone inhibits neutrophil myeloperoxidase-mediated iodination and cytotoxicity at concentrations comparable to therapeutic serum levels. Therefore, dapsone appears to protect cells from neutrophil-and eosinophil-mediated injury by directly inhibiting the generation of oxygen-derived radicals. Systemic dapsone reduces leukotriene B4 (LTB4)-stimulated inflammation in mice by inhibiting the binding of LTB4 to specific receptors on neutrophils and by inhibiting neutrophil chemotactic response to LTB4. Dapsone inhibits the generation of 5-lipooxygenase products in human polymorphonuclear leukocytes and rat mast cells in vitro and also inhibits lysosomal enzymes. Therefore, by multiple mechanisms, dapsone reduces the release of prostaglandins and leukotrienes and blocks their inflammatory effects 20, 21 . First reports on dapsone treatment in HSP were published as soon as in the 1980s 4, 5 . However, the number of reported cases is still low probably due to a small proportion of severe persistent cases and availability of other immunosupressive agents (such as azathioprine, cyclophosphamide, methotrexate and mycophenolate). Published reports on the use of dapsone in children with HSP are summarized in Table 1 .
Prognosis of HSP clearly depends on the presence of renal involvement and dapsone was shown to be ineffective in the control of HSP nephritis 6, 7 . Nevertheless, its rapid effectivity against persistent, predominantly cutaneous, manifestations of HSP was confirmed both in previous studies and by our data. The onset of effect is rapid, taking from few days to several weeks, however, recurrence of symptoms after cessation of treatment is common.
The dosage of dapsone in the presented studies ranged between 0.5 mg/kg/day and 150 mg/day with the most frequently used dose of 1 mg/kg/day ( Table 1) . As we aimed to prevent possible side effects, our first patient started with a lower dose of dapsone (0.5 mg/kg/day) with insufficient effect, whereas a dose of 1 mg/kg/day was proved to be safe and effective.
Dapsone demonstrated a favorable safety profile with rare and easily manageable adverse effects such as hypersensitivity syndrome or methemoglobinemia 9, 11 . This gives dapsone a significant advantage over corticosteroids and other immunosupressive agents. Therefore, dapsone should be considered for treatment of persistent purpura and abdominal pain in HSP especially in patients without renal involvement, such as in our three cases.
CONCLUSION
This is a report of three children with HenochSchönlein purpura (HSP) underlined by infection with Mycoplasma pneumoniae or Chlamydia pneumoniae, who presented with persistent rash and gastrointestinal symptoms resistant to standard treatment. In all cases, introduction of dapsone led to fast regression of symtoms without any reported adverse effects. We provide a comprehensive review of published pediatric cases with conclusion that dapsone treatment is beneficial especially in cases of persistent skin lesions in HSP.
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